Step by Stepa HemeOncBuddy patient portal

Neratinib

Illustration: Neratinib

Say it: neh-RA-tih-nib · Brand names: Nerlynx

Neratinib is a targeted therapy pill that blocks HER2, a protein that helps some breast cancers grow.

What it is

Some breast cancer cells have too much of a protein called HER2. Neratinib blocks HER2 and related proteins from inside the cell. This can lower the chance of the cancer coming back or slow its growth.

Often used for

How you get it

Neratinib is a pill you take by mouth at home, once a day with food. For early breast cancer it is usually taken for 1 year. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

At home

Questions to ask

Side effect guides

Sources

Quick answers

What is Neratinib?
Neratinib is a targeted therapy pill that blocks HER2, a protein that helps some breast cancers grow. Brand names: Nerlynx.
What is Neratinib used for?
early stage HER2 positive breast cancer, after finishing trastuzumab, to lower the chance it comes back; HER2 positive breast cancer that has spread, given with capecitabine.
How is Neratinib given?
Neratinib is a pill you take by mouth at home, once a day with food. For early breast cancer it is usually taken for 1 year. Your schedule may be different.
What are the common side effects of Neratinib?
Diarrhea, which is very common, especially in the first month. Feeling sick to your stomach or throwing up. Belly pain. Feeling tired or weak. Rash. Mouth sores. Not feeling hungry or losing weight. Muscle cramps.
When should I call my care team while taking Neratinib?
Diarrhea that does not get better with the medicine your team gave you, or more than 4 to 6 loose stools in a day; Feeling dizzy or faint, or not able to keep fluids down; Diarrhea with fever; Yellow skin or eyes, dark tea colored urine, or pain on the right side of your belly; A fever of 100.4 degrees Fahrenheit (38 degrees Celsius) or higher, or chills.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.